SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.

Transl Lung Cancer Res · 2021 · PMC8674596 · PMID 35004241

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

failed to reach statistical significanceP=0.067so close (0.05 < p ≤ 0.1)

Additionally activated mTOR (p-mTOR) was associated with relative resistance to lurbinectedin, but failed to reach statistical significance (P=0.067).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.